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Agricultural biotechnology’s “waves” of grain are not amber, but red, white and green. 
“Green” applications were the first to arrive: the commercial food- and feed-production 
side of agricultural biotechnology. “red” refers to plant-made pharmaceutical applications, 
whereas “white” refers to industrial applications of biotechnology (including biofuels, 
bioremediation and chemical substitutes (e.g., enzymes that can replace chlorine bleach). 
Each sector has the potential to provide significant benefits to society, if the risks—includ-
ing adverse economic impacts—can be managed to the satisfaction of key stakeholders, 
from farm to fork.
This article sums up the regulatory and liability hurdles that stand in the way of 
launching new products in each of these categories, beginning with lessons learned from 
green products. A brief review of successes and failures and existing risk-management 
methods may help overcome legal barriers to entry. Also discussed are novel barriers to 
entry posed by risks that may not be compensable, including economic losses incurred 
by other growers. 
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These liability risks and the market barriers they create are elusive and hard for American 
innovators to understand fully and manage effectively. Fortunately, industry-stewardship 
processes have evolved to anticipate and prevent novel liability risks, including the elusive 
economic-loss risks. Such stewardship standards also avoid regulatory recalls and help to 
support a sustained pipeline of productive innovation (Abramson and Carrato, 00). The 
largest of the biotech-seed companies have a wealth of experience in identity-preserved 
production. This allows them to draw upon historical data and experience as they strive 
to develop stewardship systems that meet modern standards and market expectations for 
genetic purity. 
the Product Pipeline and regulatory roadmap
The agricultural biotechnology industry can be visualized as a large oak tree, the trunk 
of which is made up of the top four crops: soy, corn, canola and cotton. Each of these 
four interwined trunks has its own history of successes and failures, and each has helped 
to established biotech crops as essential to modern agricultural production. The envi-
ronmental benefits of these genetically modified (GM) crops—from soil conservation to 
reduction in insecticide inputs—are now well documented.
Unfortunately, the tree lost entire limbs after the industry invested significant research 
funds (over $00 million in some cases) getting product lines ready for commercial 
launch. While some biotech crops have done remarkably well, there are many more in-
novative products of agricultural biotechnology that advanced to the verge of commercial 
launch, only to be shelved pending overseas regulatory approval or resolution of consumer 
concerns. These other crops lie scattered around the base of the oak like branches blown 
down by a storm. These product lines, like Bt potato, could have brought significant 
benefits to growers, consumers and the environment. to date, however, plans to revive 
the GM potato, tomato, wheat, beet, flax, barley, lettuce and other abandoned biotech 
crops are up in the air.
The challenge facing the agricultural biotechnology industry is to learn from past mis-
takes and to adjust to realities. While trees will grow in the paths of hurricanes, tropical 
species evolved roots and trunks that bend better than those of oaks. For agricultural 
biotechnology to succeed, innovators need to foresee the predictable market forces that 
may prevent product launch, and design business strategies that meet consumer demand 
without triggering the barriers erected by regulators or other consumers.
Green	Biotech:	Steadily	Growing	Despite	“ZAP”	Attacks	and	Traceability
Green-biotech products were first out of the door, paving the way for red and white prod-
ucts. The greenest of the green-biotech crops are the roundup ready™ and Bt families. 
The vast majority of soybean growers in the United States and Argentina have embraced 
roundup ready™ soybeans, in what is surely one of the fastest adoptions of new agricul-
tural technology in history. Herbicide-tolerant canola has become the dominant option in 
Canadian and US fields. Bt corn and cotton show similar track records of success, reducing 
pesticide use and demonstrating their food safety despite the skepticism of activists. 
These successful launches of multiple varieties of biotech corn, soy, cotton and canola 
are the fortunate ones, however. Many other equally useful and innovative crops have been 
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sidelined due to consumer and food-company queasiness over potential loss of market 
share. Any food company worth its salt will honor even a seemingly small percentage of 
concerned and vocal (i.e., “squeaky wheel”) customers, for perfectly valid business reasons. 
A business may not be able to justify losing a 5% share of a branded product’s market just 
to use a lower-cost input that benefits the environment (through reduced insecticide use 
or soil-conservation benefits). While this corporate marketing decision denies the majority 
of consumers the choice to support environmentally beneficial, lower-cost biotech crops, 
such is the stark reality of the modern mass-produced marketplace. 
This attention to detail led the biotech industry to build its own system for preventing 
the development of insect resistance, and to present it to the Environmental Protection 
Agency (EPA), which then imposed conditions on the growers of Bt crops to ensure 
compliance. For identity preservation, the same conscientious companies can adapt 
segregation practices, developed in seed production, to produce containment measures 
that are tailored to various types of agricultural biotechnology. These practices may be 
adjusted to ensure compliance with various levels of “tolerance” of adventitious presence 
of undesirable genotypes. 
The European Union has only recently lifted a 7-year moratorium on regulatory ap-
proval of GM crops, under threat of World trade Organization action by the United 
States, Canada and Argentina, who have lost billions in exports of grain (corn and soy) 
since 998 due to the European Union’s anti-biotech policy. This barrier to marketing of 
new biotech crops has been lifted only in part, for some varieties of biotech crops. 
to date, the first big success in biotech crops—roundup ready™ soybean—has proven 
its worth and gained access in major food and feed markets, but not environmental release. 
Major markets remain closed to many other biotech genetic events, and troubling moves 
toward traceability-based testing and associated recalls of unapproved biotech genetic 
events could make these barriers to entry pervasive and persistent. For example, the export 
barriers to entry forced soybean growers and processors (represented by the American 
Soybean Association, United Soybean Board and National Oilseeds Processors Associa-
tion, “ASA-USB-NOPA”) to develop a policy (the “eleven-point plan”) that dictates a 
closed-loop identity-preservation (CLIP) standard for varieties lacking regulatory approval 
in major export markets. As a result, upcoming Bt varieties of soybean (produced under 
license from Monsanto) can be marketed in the United States only if there is a system 
that meets CLIP’s eleven points.
As a result, Bt soybean will have to be submitted to major markets for approval (or be 
grown in a CLIP system) as long as “zero tolerance,” and testing to enforce it, are main-
tained in the European Union. The United States and its grain-exporting allies have yet 
to achieve a globally recognized tolerance for adventitious presence of GM products in 
a world where a zero adventitious presence (ZAP) regulatory import standard (enforced 
via genetic testing and mandatory disclosure laws) is increasingly prevalent. These poli-
cies are spreading to other nations that are key trading partners of the United States, 
with even more extreme standards emerging. For example, China has adopted “zero 
tolerance” for GM-food labels, which is even more strict than the European Union’s 
standard of 0.9%.
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Through a multilateral environmental agreement that became law on September , 
003, the Cartagena Protocol on Biosafety is promoting its “precautionary approach” to 
regulatory approval of biotech crops as a global standard. Paired with this delay-ridden 
approval process, the European Union has a ZAP standard for a variety that lacks approval. 
This is not unusual standing alone; the United States also has zero tolerance for unapproved 
varieties of biotech crops, but does not mandate disclosure or conduct extensive genetic 
testing (and rule-making is underway to allow some tolerance for adventitious presence 
where the variety in the pipeline is ultimately intended for food use). 
In contrast to the United States, the European Union has attempted to address toler-
ances in seed purity, only to find opposition to any number other than zero (i.e., less 
than the limit of testing). The European Union will use testing centers to track each GM 
event, forcing destruction of food based on traces of any unwanted DNA (e.g., this is 
currently occurring with one shipment to Ireland that contains Syngenta’s Bt0 corn, 
which carries a gene for antibiotic resistance that is unapproved for importation by Eu-
ropean Union nations. 
This testing process and “traceability” for GM events could become a global standard if 
the parties to the Biosafety Protocol impose, at its next meeting in Brazil (March 3–7, 
00), an international requirement that commodity shipments list all biotech genetic 
events that they “may contain” (using unique identifiers for each event). This law would 
spread traceability and labeling for GM content bound for food/feed (known as FFtL 
in industry email loops) to the parties to that protocol (0 and rising). If these nations 
are even more concerned about biotech crops than the European Union, they are free to 
impose even stricter standards than the European Union. 
The power of ZAP standards for unapproved biotech crops should not be underesti-
mated, since it empowers activists armed with genetic tests to force recalls of US shipments 
when they reach port. This is the least business-friendly arrangement imaginable, and it 
appears tailor-made for activists to rig to their tastes, testing only those corporate ship-
pers whose policies displease them. This testing for GM events is now occurring with 
shipments of corn seed and feed to the European Union and Japan. two seed shipments 
to Japan were found to contain Sygnenta’s unapproved variety Bt0. The shipment to 
Ireland may require disposal of over ,000 tonnes of corn-gluten feed.
In sum, the European Union is not alone in its quest to label GM food and trace bio-
tech crops globally, and the regulatory environment worldwide could be taking a distinct 
turn toward anti-biotech policies among US trading partners. The best example of this 
troubling trend may be China, which has its own thriving biotech research industry with 
hundreds of crops in the pipeline (and millions of GM poplar trees lining its rain-ravaged 
hillsides). China has bowed to the European Union and imposed a GM-food labeling 
standard. to complement this standard, China has legalized only commercial production 
of biotech cotton (non-food) despite pressing food-security needs (and despite reports 
of growers using pirated GM rice and corn in violation of its laws). These global trends 
are increasingly raising barriers to importation of GM crops, leaving some markets (like 
wheat and rice) without the benefits that come from biotech innovation.
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“Red”	Plant-Made	Pharmaceuticals
red biotechnology—plant-made pharmaceuticals (PMPs)—is necessary, according to 
pharmaceutical industry analysts, to meet increasing demands for protein-based large-
molecule drugs that can be produced only in living organisms. Shortages of certain new 
large-molecule drugs, which are generally produced in cell cultures, have led biotech 
companies to explore new production methods. Corn and rice are particularly suitable for 
production of proteins for pharmaceutical applications, given the relative ease of storing, 
transporting and refining the protein. 
The cost of maintaining compliance with “zero-tolerance contamination requirements” 
has led some observers to wonder whether “the economic payoffs from growing phar-
maceutical plants outweigh the costs associated with the risk of food contamination.” 
(Elbehri, 00). to weigh those costs in advance of creating a new PMP, the researcher 
needs to obtain data on identity-preservation costs, third-party oversight of the process, 
insurance coverage and other known expenses necessary to manage risk.
In general, the costs of insurance and third-party oversight for the production process 
will be hard to define. to the extent that these costs are part of a successful risk-manage-
ment strategy, however, estimates should be incorporated into long-range planning. The 
comparative costs for different regions (with varying risks) should be factored into analysis 
of the feasibility of marketing and probable return on investment. 
White	Biotechnology—Industrial	Biotech	Comes	of	Age
White biotechnology is defined as the industrial use of GM crops or microorganisms (e.g. 
bacteria, fungi) to create enzymes, proteins and other industrial compounds and materials. 
Industrial biotechnology is creating compounds that can replace of hazardous chemicals, 
providing “greening” companies with new options for reducing hazardous waste. In one 
remarkable instance of industry reaping corporate value and environmental benefit from 
biodiversity, Diversa of San Diego has taken a gene from a thermophilic bacterium that 
encodes an enzyme allowing paper-manufacturing companies to avoid using tons of toxic 
chlorine bleach (Hessler, 005).
When a plant is used as the source, rather than a microorganism, a “plant made indus-
trial product” (PMIP) results. If the PMIP crop per	se has significant export or consumer 
markets, the PMIP may encounter opposition at commercial launch. Concern has been 
expressed that PMIPS pose the same threat as PMPs, but do not have the same level of 
regulatory oversight. The PMIP has been cast as a neglected stepsister on issues like pol-
len drift, creating what appears to be a liability “bullseye.” This gap in understanding of 
pollen containment by regulators represents a threat to the food supply, since PMIPS that 
Corn	and	rice	are	particularly	suitable	for	production	of	proteins	
for	pharmaceutical	applications,	given	the	relative	ease	of	storing,	
transporting	and	refining	the	protein.	
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are not approved for use in food and could be declared an “adulterants” by the FDA, or 
trigger export losses upon detection by European-Union or other overseas officials. These 
liability risks were pointed out to USDA by the American Soybean Association and the 
regulatory gaps were closed.
Identity preservation of the crop used to produce a PMIP is necessary to deliver a pure 
product, and is equally essential to prevent the undesirable release of a PMIP in a manner 
that could lead to cataclysmic economic impacts. 
Nuisance	Claims	by	Neighboring	Growers	
Post-StarLink™ case law could allow neighboring growers to recover their economic losses 
from the source company, if they prove actual commingling of GM variety unapproved 
in the European Union [see,	In	re	StarLink	Corn	Products	Liability	Litigation,	Marvin	
Kramer	v.	Aventis	CropScience	USA	Holding	Inc.	(00),  F. Supp. d 88 (U.S. District 
Court, N.D. Illinois)].
StarLink™ was cited in a recent Canadian court decision denying a class action to organic 
growers who sought recovery of their economic losses from the marketing of GM canola 
varieties unapproved in the European Union [Hoffman	v.	Monsanto, 005 SKQB 5 
(005)]. This action was filed against Monsanto and Bayer Crop Sciences (BCS) seeking 
to enjoin the marketing of roundup ready® wheat, and also adjudicate liability for price 
impacts to canola based on “contamination” of organic and non-GM canola that could not 
be exported by Canadian farmers to the European Union. The canola sold by Monsanto 
and BCS was fully approved in Canada and posed no known health or environmental risks. 
The Hoffman court denied plaintiffs the class action they sought, but hinted at recogni-
tion of claims for violations of environmental statutes (if canola is deemed a “pollutant”) 
(http://0.83.9.88/judgments/005/QB005/ 005SKQB5.pdf ). 
The Hoffman court confirmed the basic idea that “pure economic loss” is not recoverable, 
holding that the facts did not present a situation allowing a claim for recovery of “pure 
economic loss” (with no “physical injury”), citing various policy reasons (005 SKQB 
5 at ¶ 80). The court also rejected the idea that defendants committed a “negligent 
undertaking” when they initiated identity preservation to preserve canola exports to 
Japan, then dropped that program when they received approval in Japan (even though 
the European market was still closed to any canola that was still commingled). While 
the plaintiffs still have a nuisance claim the court is willing to entertain, it remains to be 
seen how that action will play out (i.e., the plaintiffs may run into the same barrier that 
the US District Court in Eastern Missouri imposed in Monsanto	v.	Sample, if they cannot 
prove a “physical injury” from actual commingling of the GM canola with their export-
bound crops). With two causes of actions surviving, but no class certified, this decision 
(if not overturned on appeal) could lead to a flurry of individual filings if Saskatchewan’s 
certified organic farmers are willing to take Monsanto and BCS to court. 
Secrecy	of	Field	Trials
February 005 saw another landmark court decision relating to identity preservation of 
biotech crops. District Court Judge David A. Ezra rendered his final decision ordering 
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disclosure of PMP and PMIP field trials [Center	for	Food	Safety	v.	Veneman,	No.	03-CV-
621 (D. Haw, filed Nov. , 003)]. This Hawaii federal court ordered representatives of 
the USDA to hand over to Earthjustice attorneys the precise locations of open-air field 
tests of PMP crops. This was the first time the federal government was forced to disclose 
the location of field tests of GM crops. Earthjustice, representing citizen groups Center 
for Food Safety, Friends of the Earth, Pesticide Action Network North America, and 
KAHEA (The Hawaiian-Environmental Alliance) filed the lawsuit to compel USDA to 
review the environmental and public-health impacts of such activities. In August, 00, 
district court ordered the disclosure, rejecting the claims by the government and the 
Biotechnology Industry Organization (BIO) of potential “espionage,” “vandalism,” and 
“civil unrest.” The Court denied USDA and industry’s motion for a stay of disclosure, 
and the government handed the information to plaintiffs’ counsel.
The court has not yet ruled on the public-disclosure issue, however, and plaintiffs can-
not reveal the information to the general public. The disclosure should allow plaintiffs 
to pursue their original objective of seeking environmental reviews that will determine 
“how close these experiments are to conventional food crops” and ecologically sensitive 
areas [see Government Forced to Disclose Locations of test Sites of Biopharmaceutical 
Crops (USA). http://biotech. dnsalias.net/or/005/0/39.shtml].
Identity Preservation 0: the Legal tools
Where a company marketing a PMIP or PMP will encounter concern about liability 
risks, including adverse economic impacts from unwanted commingling, it can use iden-
tity-preservation measures to reassure domestic food businesses, exporters, and overseas 
importers. The use of the approved identity-preservation system will ensure that the PMIP 
is not commingled with food or grain exports. 
The	processes	for	identity	preservation	and	seed-purity	assurance	
are	rapidly	evolving	to	meet	the	demands	of	the	market.
Identity preservation of commodity grain crops to meet specialized customer needs 
has a long and successful history in seed production. The production of seeds generally 
operates on tolerances for unwanted input of various types, including genetic off-types. 
Historically, this posed no problem of commercial significance; corn out-crossed freely 
in commercial production. In today’s world, however, any corn that is bound for export 
must be “channelled” to particular elevators. One stray corn kernel that lacks regulatory 
approval in an overseas market can lead to destruction of an entire cargo, where the stan-
dard for commingling is “zero tolerance” and a trace of an unapproved variety is found (as 
occurred in 005 when the Syngenta Bt0 variety was detected in four separate shipments 
of US-origin corn). As a result, the processes for identity preservation and seed-purity 
assurance are rapidly evolving to meet the demands of the market.
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Industry	Standards
Innovation in agricultural biotechnology begins with the novel steps that lead to an 
invention meriting a patent; however, the path to market requires sound agricultural 
management. Industry standards for identity preservation provide a biotech-seed com-
pany (“the Company”) with a standard of care to follow that meets both quality-control 
and liability-prevention needs. to protect the Company’s investment in innovation, the 
developer of a new application using agricultural biotechnology, such as a PMP or PMIP, 
should adapt existing standards to create detailed methods for stewardship in the produc-
tion process. Stewardship methods for the agricultural management of biotech crops vary 
with the crop and the location of the production process. 
The simplest route to maintaining identity preservation is to anticipate the demands of 
customers and regulatory agencies, develop an industry standard and stick to it. Industry 
organizations, led by BIO, developed the Confinement Analysis and Critical Control 
Point (CACCP) concept for molecular farming applications including ProdiGene’s corn-
produced vaccine for piglets, and PMIPs (Phillips, 00).
A sound model for identity preservation of PMPs and PMIPs was generated by the 
Canadian Food Inspection Agency (CFIA, 00). After reviewing various methods for 
identity preservation, the CFIA recommended, in its January 00 report, eleven elements 
of confinement systems for “molecular farming crops” (i.e. PMPs and PMIPs). This paper 
is patterned after the CACCP system developed by BIO, and it mandates supervision 
by a third party, preferably regulators. One item that is missing, in comparison to the 
ASA/USB/NOPA “eleven point plan” is the express assumption of liability for system 
failure attributable to the biotech-seed company.
Identity preservation methods have been developed in consultation with growers 
and grain handlers. The ASA/USB/NOPA CLIP process has been used since 998 to 
protect US-export flows of soybeans to the European Union and other major markets, 
while allowing limited releases of new biotech soybeans. The ASA/USB/NOPA “eleven 
point plan” for the CLIP process requires the biotech-seed company to assume liability 
for system failure. This generally precludes the company from using contractual clauses 
that unfairly shift to growers all the risk of commingling. Properly and fairly operated, 
such systems for identity preservation will continue to provide grower and biotech-seed 
companies with protection from liability lawsuits. 
Similarly, the National Corn Growers has developed the “Know Before You Grow” 
process for identity preservation of corn-gluten feed that is bound for export. While 
exports of whole corn to the European Union have been foreclosed since 997 by the 
commingling of GM events that lacked regulatory approval, recent efforts to comply with 
the European Union’s new traceability directives (effective /8/0) have succeeded in 
keeping the $00 million per year in corn-gluten feed flowing to the European Union 
from the United States.
Identity-preservation methodology has been developed through trial and error, as 
major life-sciences companies developed their stewardship programs in consultation 
with growers associations. The ASA/USB/NOPA CLIP process has been applied for the 
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production of DuPont’s high oleic soybean, which is used in specialized biodegradable 
lubricant applications. This same eleven-point plan was previously presented in 998 to 
AgrEvo USA, the corporate predecessor of Aventis Crop Sciences, Inc., which adopted 
it for a Liberty Link® soybean stewardship program (which soybean was not, however, 
marketed in the United States, in contrast to the high oleic cultivar).
Under the CLIP system, the first level of concern involves the terms of the contract 
for sale of the biotech seed. The contract with the grower of the specialty PMP or PMIP 
crop should have conditions similar to those for certified seed production or federally 
permitted field trials, including regular inspections and scientifically defensible minimum 
isolation distances from neighboring crops. The contract should also guarantee the grower 
a premium adequate to cover the costs of preventing commingling with other crops (field 
isolation and inspection requirements can be costly for the grower). Only contracted 
growers should be allowed to grow the specialty crop. 
The second level concerns planning to coordinate the harvest process. Growers need 
training to ensure that combines and transport vehicles do not cause commingling and are 
cleaned out to industry standards. The Company needs to identify elevators where there 
is willingness to accept the identity-preserved production while keeping it completely 
separate from all other commodities. These elevators should be confined to particular 
regions, not widely scattered throughout the farm belt. Coordination of inspections 
between the elevator and the field inspectors will allow the midseason yield estimates 
to be matched to the actual delivery, to ensure that the entire crop is delivered and not 
diverted to other uses.
Thirdly, the CLIP system requires that the Company contract with a third party to 
certify the process. There are seed-certifying agencies that have conducted such audits 
for decades [e.g., the Association of Official Seed Certifying Agencies (http://www.aosca.
org) and newer specialized operations such as Novecta (http://www.novecta.com) and the 
United States Department of Agriculture’s Process Verified Program (http://processveri-
fied.usda.gov)].
Lastly, the CLIP system requires that the Company agrees to assume—and not attempt 
to disclaim or limit—the legal and financial liability that arises from negligence or other 
breaches. Under the ASA/USB/NOPA CLIP system, the focus is upon crops that may 
lead to lost trade with overseas soybean export markets. Commingling of an unapproved 
variety, in particular a PMIP or PMP variety that is not approved for any food or feed use 
at any tolerance, can lead to cataclysmic economic loss in major export crops. 
These systems have not worked perfectly, as the StarLink™ corn recall and ProdiGene 
commingling incidents illustrate. In the StarLink™ episode, Aventis Crop Sciences had 
been warned of the potentially “cataclysmic” economic impacts that existing US precedent 
pointed toward (Censky, 999). Despite this warning, Aventis sold StarLink™ corn with 
inadequate stewardship. Along the same lines, tiny ProdiGene’s sprouting corn volunteers 
contaminated a soybean field, despite a USDA inspector’s warning. This commingling 
incident ended at one elevator, but still required an interest-free loan from USDA to 
maintain a viable business.
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Detecting	Gaps	in	Regulation	and	Stewardship
The practice of identifying and managing risks adequately is not a perfect process, and 
troublesome gaps have emerged in regulation of particular aspects of biotechnology. One 
example in USDA regulation involves setback distances to preclude pollen drift from 
PMP plants. This glaring gap in regulatory oversight was apparent to anyone comparing 
the planting distances in the regulations, and it was quickly corrected through the timely 
intervention of the American Soybean Association. Had this gap not been corrected, the 
overview of a “bullseye” made a target for plaintiffs’ attorneys that exposed a failure to 
exercise “due care” in the segregation of crops.
This “biotech bullseye” episode provides a “near miss” in liability law, which helped to 
prevent serious commingling with PMPs. It also provides confirmation that the existing 
stewardship practices of the most responsible seed companies (Monsanto, DuPont, etc.) 
were more alert to the risks of out-crossing from PMP plants than were USDA regulators. 
The seed industry had already determined through testing that a -mile planting distance 
is required to maintain a very low tolerance for out-crossing in corn production. These 
seed companies foresaw the need for stewardship standards that track potential liability 
risks, including those that might elude a busy regulatory agency. 
This does not mean that USDA is incompetent in terms of managing risk, but merely 
highlights the need to supplement regulatory review with industry oversight. It is a basic 
principle of product-liability law that even the most proactive regulatory authority can 
only set a “one size fits all” minimum, based on limited knowledge of the product, while 
the alert company is expected to know its product and foresee its hazards with more 
precision. 
ISO 9000 and ISO 000 are process standards that can be used to identify customer 
needs and product hazards, and to implement processes to prevent both product-related 
(under ISO 9000) and environmental liability (under ISO 000). Biotech-seed compa-
nies may use these standards or a modified system that is not certified by an ISO registrar 
but still provides necessary oversight that regulation cannot impart.
The US Supreme Court recently affirmed the role of industry in post-market surveil-
lance for product risks. In Bates	v.	Dow (005), the Court put all pesticide manufacturers 
on notice of the power of tort law to keep them alert to new risks that emerge over time, 
which may elude the detection of regulators. This landmark decision expands the horizon 
of biotech-seed-company liability for certain EPA-registered crops, and creates a feedback 
loop, as described by Justice Stevens, requiring companies to adjust their practices to avoid 
the adverse event that triggered the state’s tort law. 
Companies that do not quickly react to feedback can find their markets disappearing 
due to consumer opposition. In the PMP setting, this occurred in the ProdiGene case; 
failure to remove volunteer PMP corn from a soybean field led to a $3 million loss of 
the elevator’s commingled contents. Subsequently, the biotech industry implemented 
additional safeguards and regulatory agencies reviewed inspection policies.
However, policy positions of major players in the chain of commerce shifted to a 
more anti-biotechnology position after StarLink™ (with help from the ProdiGene-PMP 
commingling event). The Grocery Manufacturers of America (GMA) began insisting on 
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abandoning any use of food crops for PMP production, whereas grower and grain associa-
tions merely insisted on the use of well tested closed-loop identity preservation. GMA’s 
position was not irrational or poorly considered; its board is made up of CEOs whose 
judgment is well informed. This position reflected a loss of trust from a critical group of 
customers—the primary buyers of “green” biotechnology products had lost faith in the 
ability of the makers of “white” and “red” products to maintain necessary segregation in 
production. Winning back trust, once lost, is much more difficult than the effort required 
not to breach that trust in the first instance. 
Will a Liability Backlash Follow the European Union’s 
Precautionary Approach?
two potential backlashes are created by the European Union’s ZAP approach to GM 
crops. First and foremost, there are hazards from food that are heightened by anti-bio-
tech regulations that deny consumers access to use of the best available technologies for 
controlling carcinogenic mycotoxins in their staple food supply. These toxins, which can 
be better controlled with use of Bt corn, are not a hazard of significance in the United 
States or the European Union (which have resources to detect it and avoid exposure). 
However, they pose a significant risk to the health of mothers and children in Africa, 
Central America and Mexico where less-varied diets lead to higher corn consumption in 
farming communities. 
The European Union has implemented both GM labeling and ZAP regulatory ap-
proval by invoking the “precautionary principle,” an approach to regulatory approval 
that would consider the presence of antibiotic-resistance genes in corn-gluten feed cause 
for concern and, paradoxically, would mandate the destruction of said feed. This would 
apply even if the destroyed feed would be healthier than the alternative due to lower 
mycotoxin levels. 
Although liability laws dictate the use of the best available technology to avoid feeding 
carcinogens to children and pregnant women, the regulatory environment instituted by 
the European Union to meet “collective preferences” operates to ban any trace of this best 
available technology—setting up a future where liability could apply even if the company 
in question were to assert as a defense in court, “The European Union made me do it.” 
The law in the European Union and the United States may provide a presumption of 
reasonable behavior based on regulatory requirements, but it can be overcome by a tort 
theory stating that there was a risk that required a warning or could be implemented at 
minimal cost (in the case of biotech crops, the cost of using them could be lower). 
There	are	hazards	from	food	that	are	heightened	by	anti-biotech	
regulations	that	deny	consumers	access	to	use	of	the	best	available	
technologies	for	controlling	carcinogenic	mycotoxins	in	their	staple	
food	supply..
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The anti-biotech activists who run the show in Germany have succeeded in creating 
their own innovative approach to liability, which helps to close the door to any grower who 
might attempt to use the “best available technology” for mycotoxin-insecticide reduction 
(the European Union has approved some varieties of Bt corn). German growers of biotech 
crops are discouraged by a GM liability law that forces them to avoid any commingling 
with other growers, who may have agreed to supply non-GM products. 
The concept of protecting the non-GM grower’s contractual promise of “zero” is also 
emerging in the negotiations of the Biosafety Protocol’s liability regime, which is now 
underway with hopes of producing a text by September , 007, for approval by the 
parties to the Biosafety Protocol. Activists have suggested innovations in liability law 
that would:
• reverse the burden of proof to the GM-crop grower or grain exporter,
• protect the economic loss of the non-GM grower (who may be harboring a reser-
voir of “biodiversity” in his choice of seed), and
• place the ultimate blame on the company that developed the biotech seed, since 
the GM event that “harmed” the non-GM grower can be traced.
The seed of anti-biotech liability law now sprouting in Germany could have a broad 
dispersal if the parties to the Biosafety Protocol do not come to their senses and reject 
such standards.
With member states free to impose their own liability regimes like this one, and balk 
at European Union-wide regulatory approval, the European Union’s misguided anti-
biotech-innovation policy could take decades—or an entire century—to reverse, even 
if it is shown without dispute to have caused well documented harm to human health 
and the environment. to ensure that the costs of the European Union’s precautionary 
approach and ZAP testing are counted, foundations that care about neglected popula-
tions of people (e.g., African refugees who are denied food aid based on traces of locally 
unapproved GM events) and neglected plants (e.g., wild and indigenous soybean, rice and 
other crops) need to stand up to the challenge of tracking the harm that can be caused 
by misguided regulation.
State Law Barriers and tools for Marketing Biotech Crops
While the US federal regulatory system is streamlined and efficiently operating to manage 
risks, there are emerging roles for states, counties and cities to react to authorities that 
seek to protect economic interests and social, cultural or indigenous concerns. These local 
While	the	US	federal	regulatory	system	is	streamlined	and	
efficiently	operating	to	manage	risks,	there	are	emerging	roles	for	
states,	counties	and	cities	to	react	to	authorities	that	seek	to	protect	
economic	interests	and	social,	cultural	or	indigenous	concerns.
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authorities may be reacting to international opposition that limits markets from particular 
states. In response to California’s rice industry, a bill was passed in 000, Assembly Bill 
, that licensed all rice for its economic impacts—specifically addressing the threat that 
biotech rice poses to export markets; Arkansas passed a similar law in March , 005, 
that gives the Arkansas State Plant Board the power to regulate “commercial impact” of 
rice commingling—without specifically mentioning biotech rice (HB 57, 3//05).
For example, Iowa has passed a law precluding any county from declaring itself GM 
free (a reaction, no doubt, to the three California counties that went “GM free” in 00). 
Iowa grower Bill Horan just reported that production of a PMP will finally be allowed 
to occur in Iowa, at a military base over a mile from other corn production. The Iowa 
experiment now underway will provide more data on the cost-effectiveness of growing 
pharmaceutical corn in the nation’s largest corn-producing state. 
The story of Ventria’s rice provides a narrative that touches upon the entire range of 
regulatory and liability issues facing new PMPs launched in the United States, and the 
key stakeholders in the commercial launch of a PMP. Ventria started out trying for state-
level regulatory approval in California. While the California rice Commission approved 
Ventria’s application, leaving it up to the state Department of Agriculture to decide, the 
announcement that a public hearing would be held resulted in Ventria’s choosing to 
relocate its operations to Missouri, giving up on California approval.
Missouri proved inhospitable to Ventria as well, as major food producers who use Mis-
souri and Arkansas rice expressed concern about commingling. Press reports indicated 
that a counterseasonal South American site may be next in line, or a small plot in North 
Carolina.
If	the	agricultural	biotechnology	industry	is	going	to	meet	
customer	expectations	for	segregation	of	the	green,	white	and	red,	
it	may	need	to	work	with	growers	to	create	districts	that	establish	
identity	preservation	as	a	matter	of	civic	law.
One little known legal aspect of the Ventria story is the unused Missouri “grower 
district” statute that was enacted in late 00 (effective January , 005) with Ventria in 
mind (but not used by Ventria) to line up growers in a dedicated region (a solution that 
might have reassured rice interests opposed to Ventria’s plans). A future PMP- or PMIP-
production system can avail itself of this tool, however. This concept of a grower district 
appears in a new Missouri statute that was passed in 00, around the time frame when 
Ventria moved its operations from California to Missouri in early 005. If the agricultural 
biotechnology industry is going to meet customer expectations for segregation of the 
green, white and red, it may need to work with growers to create districts that establish 
identity preservation as a matter of civic law.
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Other novel agricultural technologies have arrived on the scene with similar seg-
regation issues. Canola only recently became an edible food product by innovations 
adjusting rapeseed’s nutritional profile. The canola industry uses a variety of production 
methods to maintain the necessary segregation, including grower districts in Idaho and 
Washington. 
Another angle on PMP production that is under review is simply to go underground 
in the farm belt. This allows production to occur close to existing processing centers in 
the midwest (e.g. Sigma Aldrich in St. Louis, MO), while avoiding the controversy and 
exposure to eco-terrorism that can occur aboveground. Like any innovative step, however, 
this option will have to prove its economic worth before innovators will adopt it.
Conclusion
Despite past successes, and the knowledge gained from failures and near misses, the 
road to future commercial success in agricultural biotechnology remains as full of hid-
den economic hazards as the road to the Baghdad airport. The European Union and its 
like-minded trading partners will continue to hold their ZAP standards over the heads 
of grain exporters and will increasingly drive innovation in agricultural biotechnology 
into contained, closed-loop production systems. Like a game of three-dimensional chess, 
biotech crops will face three levels of regulatory oversight, starting with federal approvals, 
but with more requirements emerging at the state level (even in counties and/or cities), 
and overseas. For many biotech crops, international approvals that may be required 
prior to market launch in the United States (for soybean, rice, wheat and other primarily 
export-bound crops). As a result, US agricultural biotechnology operations will need to 
maintain perfect divisions between the green, white and red sectors—as neatly divided 
in the fields of America as the stripes in the Italian or Irish flags, which do not blur their 
colors together.
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